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Mal de Meleda is a rare, autosomal recessive form
of palmoplantar keratoderma. The disease has been
mapped to chromosome 8qter, and in a recent study
mutations in the ARS gene have been identi¢ed in fa-
milies with this disorder. Here, we report two unrelated
families with mal de Meleda, in which two di¡erent
homozygous mutations in the ARS gene were identi-
¢ed. These ¢ndings support the notion that mutations
in the ARS gene are pathogenic in mal de Meleda.
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M
al de Meleda (MdM) (keratosis palmoplantaris
transgrediens, OMIM# 248300) is a rare form
of palmoplantar keratoderma (PPK). It is an
autosomal recessive disorder characterized by er-
ythema and hyperkeratosis of the palms and
soles with sharp demarcation, extending to the dorsal aspects of
the hands and feet (known as transgrediens) (Hovorka and Eh-
lers, 1897; Schnyder et al, 1969). The palmoplantar hyperkeratosis
is usually accompanied by hyperhidrosis, maceration, fetid odor,
and painful ¢ssures. Other associated ¢ndings include nail ab-
normalities, keratotic plaques over the joints, perioral erythema,
brachydactyly, and pseudoainhum (Bergman et al, 1993).
Recently, homozygous mutations in the ARS (component B)
(ARS) gene were identi¢ed in families with MdM, implicating
ARS as the susceptibility gene for this disease (Fischer et al,
2001). Subsequently, a patient with MdM lacking mutations in
ARS was reported, suggesting genetic heterogeneity (van Steen-
sel et al, 2002). In this report, we describe two unrelated families
with MdM in which two di¡erent homozygous mutations in the
ARS gene were identi¢ed. Of interest, these mutations are the
same as reported previously by Fischer et al.
MATERIALS AND METHODS
Genomic DNA was extracted from whole blood using a QIAamp Blood
Maxi Kit (Qiagen,Valencia, CA). The three exons of the ARS gene were
ampli¢ed by polymerase chain reaction (PCR) using the primers described
previously (Fischer et al, 2001). For mutation detection, the PCR products
were sequenced using an Applied Biosystem 310 automated sequencing
system. The PCR products were digested with BspMI or DdeI at 371C for
3 h and analyzed on 1.5% agarose/TBE minigels.
RESULTS
Clinical data The clinical ¢ndings for both families have been
described previously (Ayman et al, 2000). Family 1was of Kurdish
descent and family 2 of Turkish descent. Consanguinity was
present in both families. All a¡ected individuals showed classical
¢ndings of MdM, hyperkeratosis, and erythema of the palms and
soles with transgrediens (Figs 1b, 2b). In family 1, although both
II-2 (36 y old) and II-7 (18 y old) had subungual hyperkeratosis of
the toenails as well as hyperkeratotic plaques on the knees, these
skin ¢ndings were absent in III-1 (2 y old). In II-1 (34 y old) of
family 2, perioral erythema was observed with neither nail
involvement nor hyperkeratotic plaques.
Mutation detection and con¢rmation In family 1, direct
sequencing of the ARS gene £anking exon 2 showed a
homozygous deletion of T at nucleotide 82 (82delT), resulting in
a premature stop codon at residue 32. The a¡ected individuals in
this family, II-2, II-7, and III-1, all showed the homozygous
82delT mutation, whereas the carriers, II-3 and II-4, displayed a
heterozygous sequence (Fig 1c). 82delT abolishes a restriction
endonuclease site for the enzyme BspMI, which was used to
con¢rm the mutation (Fig 1d).
In family 2, a homozygous C toT transition at nucleotide 286
in exon 3, leading to a conversion of an arginine residue (CGA)
to a stop codon (TGA) at amino acid 96, was identi¢ed.Whereas
the homozygous C286T mutation was observed in the proband,
her parents, I-1 and I-2, both displayed a heterozygous sequence
(Fig 2c). This mutation, designated C286T, creates a restriction
endonuclease site for the enzyme DdeI, which was used to
con¢rm the mutation (Fig 2d). The sequence alterations found
in these families were not observed in 50 unrelated, una¡ected
Turkish and Kurdish controls.
DISCUSSION
The ARS gene is predicted to consist of three translated exons,
and encodes a 103 amino acid protein, SLURP-1 (secreted Ly-6/
uPAR related protein 1). SLURP-1 belongs to the Ly-6/uPAR fa-
mily of proteins, which typically contain a highly conserved pat-
tern of disul¢de bridges and a gene structure of four exons, the
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¢rst of which is untranslated (Adermann et al, 1999). Although
members of the Ly-6/uPAR family have been implicated in
transmembrane signal transduction, cell activation, and cell
adhesion, the function of SLURP-1 remains unknown. The
SLURP-1 mRNA expression has been demonstrated by reverse
transcription PCR in keratinocytes from plantar and truncal
skin, the foreskin, the scalp skin, and fetal bladder. Its mRNA
expression was not observed in most tissues, however, including
adult liver, lung, kidney, colon, uterus, and ¢broblasts (Fischer
et al, 2001).
In 2001, 12 families of Algerian descent and seven families
from Croatia with MdM were shown to exhibit mutations in
the ARS gene. Speci¢cally, three di¡erent homozygous muta-
tions, 82delT, 178þ1G-A, and C286T, were identi¢ed in these fa-
milies (Fischer et al, 2001). Of interest, the two families we
examined also exhibited homozygous 82delT and C286T muta-
tions in the ARS gene. These mutations are observed in amino
acids that are conserved among species in which ARS has been
cloned. Both mutations result in premature stop codons, and thus
are predicted to lead to the synthesis of truncated protein or to
the degradation of transcripts via nonsense mediated mRNA de-
cay. C286Toccurs in a CpG-containing arginine codon found in
exon 3 of the ARS gene. Deamination of CpG dinucleotides is
the most common mechanism underlying point mutations in
humans. Although C286T mutation is towards the end of the
protein, the truncated protein lacks a cysteine implicated in one
of the highly conserved disul¢de bridges.
MdM is characterized by transgressive PPK and a variety of
associated ¢ndings, and shows clinical variability among the pa-
tients. Recently some patients with classical MdM phenotype
have failed to show linkage to the MdM interval (Lestringant
et al, 2001) or lacked mutations in the ARS gene (van Steensel
et al, 2002), suggesting genetic heterogeneity. The two families
described here both exhibit classical transgressive PPK. In addi-
tion, patients in family 1 with the 82delT mutation demonstrate
hyperkeratotic plaques (lichenoid plaques) on the knees and sub-
ungual hyperkeratosis of the toenails. The patient in family 2
with the C286Tmutation only has perioral erythema as the asso-
ciated ¢nding. Our patients lacked brachydactyly, pseudoainhum,
and knuckle pads. The identi¢cation of recurrent mutations sug-
gests that these may be hot-spot mutations within the ARS gene,
or may implicate a common ancestral allele. Further work in the
mutational spectrum of ARS in other MdM families will help
to clarify these issues. Our data con¢rm the ¢ndings of Fischer
Figure1. Clinical data and genetic analysis of family 1with MdM. (a) Pedigree of the family. Gray symbols indicate family members that are predicted
to be carriers, whose DNA have not been analyzed. (b) Palmoplantar erythema and keratoderma with transgrediens. (c) DNA sequence of exon 2 from
control, heterozygous carrier, and homozygous a¡ected individuals. (d) The top ¢gure shows the 403 bp PCR ampli¢cation of exon 2 of the ARS gene, in
II-2, II-3, II-4, II-7, III-1, and two control samples. The bottom ¢gure shows BspMI digestion of the PCR samples, which cuts the wild-type allele in 120,
105, 90, and 88 bp fragments. The 82delT mutation abolishes the BspMI site at nucleotide 120 of the PCR product, and therefore digestion of the mutant
allele results in three fragments: 209, 105, and 88 bp.
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et al and support the notion that mutations in the ARS gene are
pathogenic in MdM.
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Figure 2. Clinical data and genetic analysis of family 2 with MdM. (a) Pedigree of the family. (b) Clinical data. (c) DNA sequence of exon 3 from
control, heterozygous carrier, and homozygous a¡ected individuals. (d) Restriction endonuclease analysis with the enzyme DdeI. DdeI digestion cuts the 448
bp PCR product into 272, 90, 65, and 21 bp fragments on the wild-type allele. The C286Tmutation creates a new DdeI site at nucleotide 216 of the PCR
product, and therefore digestion of the mutant allele results in fragments of 216, 90, 65, 56, and 21 bp.
98 WARD ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
